Sur1–Trpm4-Promising Target for Brain Edema Treatment in Brain Edema: From Molecular Mechanisms to Clinical Practice

Sebastian Urday, Kevin N. Sheth, J. Marc Simard

Research output: Chapter in Book/Report/Conference proceedingChapter


Brain edema after acute neurological injury causes significant morbidity and mortality. In this chapter, we highlight the critical role of the sulfonylurea receptor 1–transient receptor potential M4 (SUR1–TRPM4) channel in the pathogenesis of brain edema across various neurocritical care conditions. We emphasize that SUR1–TRPM4 activation is pivotal at every stage in edema formation. It contributes to every type of edema (cytotoxic, ionic, and vasogenic) and to total microvascular failure, which results in the extravasation of blood and the formation of petechial hemorrhages. We present examples from experimental models that demonstrate that selective blockade of SUR1–TRPM4 with glibenclamide results in improvement in edema, lesion volume, mortality, and neurological function. Clinical studies supporting the role of SUR1–TRPM4 in edema formation in humans are also presented. Although definitive phase III studies are needed, the ability to block SUR1–TRPM4 over a broad time window with a safe medication (glibenclamide) is emerging as a highly promising approach to treat brain edema.

Original languageEnglish (US)
Title of host publicationBrain Edema
Subtitle of host publicationFrom Molecular Mechanisms to Clinical Practice
Number of pages16
ISBN (Electronic)9780128031964
ISBN (Print)9780128031971
StatePublished - Jan 1 2017
Externally publishedYes


  • SUR1–TRPM4
  • brain edema
  • glibenclamide
  • microvascular failure

ASJC Scopus subject areas

  • General Medicine
  • General Neuroscience


Dive into the research topics of 'Sur1–Trpm4-Promising Target for Brain Edema Treatment in Brain Edema: From Molecular Mechanisms to Clinical Practice'. Together they form a unique fingerprint.

Cite this